Biochemical and Survival Outcomes in Patients With T3 Prostate Adenocarcinoma Treated With Brachytherapy

Autor: B.J. Moran, M.H. Braccioforte, Abhishek A. Solanki
Rok vydání: 2014
Předmět:
Zdroj: International Journal of Radiation Oncology*Biology*Physics. 90:S450
ISSN: 0360-3016
Popis: Purpose/Objective(s): To evaluate the freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), and overall survival (OS) in patients with cT3a-b prostate adenocarcinoma treated at a single institution. Materials/Methods: One hundred seven patients with cT3a-b, N0, M0 prostate adenocarcinoma underwent I-125 (72%) or Pd-103 (28%) low dose rate brachytherapy from 1998-2007. Seventy-five patients (70%) received supplemental external beam radiation therapy as part of combined modality therapy (CMT). Thirty-two patients (30%) underwent implant alone (MT). Ninety-two patients (86%) received androgen deprivation therapy (ADT). Median (range) age, pre-treatment PSA (iPSA), duration of ADT and follow-up were 69 years (47-93), 12.7 ng/ml (1.4-160), 4 months (2-36) and 73 months (9-160), respectively. Fifty-five men (51%) had Gleason sum (GS) 8-10. Eighty-nine patients (86%) had 50% of cores involved. Univariate analysis (UVA) was performed using the logrank test and Cox proportional hazards for continuous variables with the following covariates: age, T-stage (T3a vs. T3b), GS, iPSA, percent positive cores (PPC), ADT use, and implant setting (CMT vs. MT). Multivariable analysis (MVA) was performed using Cox proportional hazards modeling and included T-stage, GS, iPSA and all covariates with p-value
Databáze: OpenAIRE